| 查看: 770 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
材料工程085601，270求调剂
已经有24人回复
-
085404 293求调剂
已经有3人回复
-
调剂
已经有21人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有15人回复
-
08工科求调剂290分
已经有12人回复
-
286求调剂
已经有16人回复
-
材料类284调剂
已经有24人回复
-
考研调剂-材料类-284
已经有14人回复
-
327求调剂
已经有11人回复
-
一志愿985初试354分生物调剂
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
沈阳化工大学环境学院生物与医药、药学、化学、安全工程、环境工程等可调剂，名额充裕
+1/482
-
浙江师范大学数理医学招聘专任教师
+5/345
-
湖北汽车工业学院汽车材料学院2026年接收调剂研究生（新能源电池方向）
+2/50
-
延安大学长江学者团队招收材料、化工相关领域的调剂研究生数名
+1/41
-
复旦大学院士团队招聘药学博士后/科研助理
+1/34
-
爆 名额多 河北大学招收生物与医药专业调剂考生
+2/32
-
澳科大王晓琳/郭辉课题组招聘—澳门青年学者计划、澳门青年学者计划（湾区项目）
+2/28
-
哈尔滨工业大学化工学院中俄联合办学硕士生招生
+1/21
-
上海应用技术大学姚子建课题组招生，点击就送研究生学历
+1/20
-
中国石油大学（北京）国家级大人才团队博士招生1名：化学、材料、石油工程：油田化学
+1/18
-
香港科技大学 机器人/生物医学
+1/9
-
东北石油大学招生调剂硕士生若干
+1/6
-
招收2026级研究生
+1/5
-
齐鲁工业大学 国家重点实验室-新能源、锂离子电池、材料、化学方向
+1/5
-
吉林工程技术师范学院 材料与化工 （0856） 招收调剂
+1/5
-
江西水利电力大学市政工程接受调剂
+1/5
-
基于质谱从头测序与蛋白语言模型的肿瘤新抗原识别新技术研发 （杭州)
+1/5
-
南昌大学工程建设学院2026年招聘2名科研助理
+1/4
-
齐齐哈尔大学李莉课题组诚招2026级考研调剂生（学硕和专硕）
+1/3
-
军事医学研究员毒物药物研究所药理学生物技术药物代谢方向招收调剂生 4名
+1/2
|
b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. 术后48小时但不超过5天未使用抗生素所得的腹内脓肿（包括肝，脾）的患者，其脓肿是由于感染所引起的 |
8楼2011-01-12 10:42:52
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
